Glutathione for Immune Function

Verdict: Weak, surrogate-only evidence; unproven for immunity

Oral glutathione is not proven to strengthen immune function in healthy people. The only human trials are very small and measured lab markers rather than real outcomes like fewer infections, so this rates as weak (C) evidence.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The human evidence amounts to two tiny trials measuring surrogate markers, not actual illness. A 54-person double-blind RCT (PMID 24791752) found high-dose oral glutathione raised body glutathione stores and more than doubled natural killer (NK) cell activity at three months, but those gains vanished after a one-month washout. A 12-person pilot of liposomal glutathione (PMID 28853742) reported large jumps in NK activity, yet it had no placebo group, was funded by a supplement maker, and its authors flagged limited statistical power.

Crucially, no study tracked clinical endpoints such as infection rates, illness duration, or vaccine response. A 2000 review (PMID 11115795) concluded plainly that there is no evidence glutathione boosts infection resistance or vaccine response in healthy people; any benefit was confined to glutathione-depleted disease states like HIV. Oral glutathione is also poorly absorbed, and a meta-analysis disputes even the body-store findings.

No major health authority endorses this use. The FDA, NHS, EFSA, and WHO statements address injectable skin-whitening safety rather than oral immune benefit, and NIH ODS, Mayo Clinic, and Harvard Health do not address it at all. With only small, surrogate-marker, partly industry-funded preliminary data and a vague 'immune function' claim, a Weak (C) grade with a warning is appropriate.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.50
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
77%
Broadly consistent
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.45
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.55
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.497
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (3)L2 · primary research & systematic reviews

Randomized controlled trial of oral glutathione supplementation on body stores of glutathione
PMID: 24791752 2015 RCT (double-blind) n = 54
Finding: High-dose group showed 30-35% rise in erythrocyte/plasma/lymphocyte GSH and 260% in buccal cells (P<0.05). Natural killer cell cytotoxicity increased more than two-fold versus placebo at 3 months in the high-dose group (P<0.05). GSH levels returned to baseline after a 1-month washout.
Government Effect size: NK cytotoxicity >2-fold increase vs placebo at 3 months (high-dose)
View on PubMed
Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function
PMID: 28853742 2018 隨機對照試驗 n = 12
Finding: Whole-blood GSH rose up to 40% and PBMC GSH up to 100% at 2 weeks (P<0.05). NK cell cytotoxicity elevated up to 400% and lymphocyte proliferation up to 60% at 2 weeks (P<0.05). Authors explicitly note limited statistical power due to the small sample.
🟠 Limited quality ⚠️ Industry-funded Effect size: NK cytotoxicity +up to 400%; lymphocyte proliferation +up to 60% at 2 weeks
View on PubMed
Glutathione and immune function
PMID: 11115795 2000 Other
Finding: Lymphocyte function depends on a tightly balanced intracellular glutathione level. Glutathione (or cysteine) supplementation restored near-normal NK activity in HIV-infected patients in two RCTs, but the review states there is no indication that resistance to infection or vaccine response is enhanced in healthy human subjects by glutathione or cysteine supplementation.
Effect size: n/a (review) — benefit confined to GSH-depleted disease states
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Against
FDA warns compounders not to use glutathione L-reduced powder distributed by Letco Medical to compound sterile injectable drugs for patients. The L-glutathione powder was labeled with 'Caution: Dietary Supplement' and should not have been used to compound sterile injectable drugs. source↗
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Cautious
由圓酵母(Torula yeast)發酵製成之食品原料穀胱甘肽,其每日食用限量為二百五十毫克,且應標示「對穀胱甘肽過敏者、孕婦、哺乳婦女及嬰幼兒應避免食用」之警語字樣。 source↗
L5c Cleveland Clinic
Neutral
L5e Specialty Society (condition-mapped)
Not addressed
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬3 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-immune-function-INT-glutathione-001 繁體中文版 →